STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors

Nature Medicine

Volumn 16, Issue 12, 2010, Pages 1421-1428

  Lee, Heehyoung ^a   Deng, Jiehui ^a   Kujawski, MacIej ^a   Yang, Chunmei ^a   Liu, Yong ^a   Herrmann, Andreas ^a   Kortylewski, Marcin ^a   Horne, David ^a   Somlo, George ^a   Forman, Stephen ^a   Jove, Richard ^a   Yu, Hua ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LYSOPHOSPHOLIPID; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR 1; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER GROWTH; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; TUMOR; UPREGULATION;

ANIMALS; CHROMATIN IMMUNOPRECIPITATION; DNA PRIMERS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEEDBACK, PHYSIOLOGICAL; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; INTERLEUKIN-6; MICE; MICE, KNOCKOUT; MICROSCOPY, CONFOCAL; NEOPLASMS; RECEPTORS, LYSOSPHINGOLIPID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STAT3 TRANSCRIPTION FACTOR;

EID: 78649982367     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2250     Document Type: Article

References (41)

1. Catlett-Falcone, R. et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10, 105-115 (1999).
2. Rebouissou, S. et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 457, 200-204 (2009).
3. Yu, H. & Jove, R. The STATs of cancer-new molecular targets come of age. Nat. Rev. Cancer 4, 97-105 (2004).
4. Yu, H., Pardoll, D. & Jove, R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9, 798-809 (2009).
5. Yu, H., Kortylewski, M. & Pardoll, D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 7, 41-51 (2007).
6. Gao, S.P. et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J. Clin. Invest. 117, 3846-3856 (2007).
7. Bollrath, J. et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15, 91-102 (2009).
8. Grivennikov, S. et al. IL-6 and stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15, 103-113 (2009).
9. Hedvat, M. et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 16, 487-497 (2009).
10. Ara, T. et al. Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Res. 69, 329-337 (2009).
11. Wang, L. et al. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J. Exp. Med. 206, 1457-1464 (2009).
12. Yoshimura, A., Naka, T. & Kubo, M. SOCS proteins, cytokine signalling and immune regulation. Nat. Rev. Immunol. 7, 454-465 (2007).
13. Auernhammer, C.J., Bousquet, C. & Melmed, S. Autoregulation of pituitary corticotroph SOCS-3 expression: characterization of the murine SOCS-3 promoter. Proc. Natl. Acad. Sci. USA 96, 6964-6969 (1999).
14. Lee, H. et al. Persistently activated Stat3 maintains constitutive NF-?B activity in tumors. Cancer Cell 15, 283-293 (2009).
15. Sumimoto, H., Imabayashi, F., Iwata, T. & Kawakami, Y. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J. Exp. Med. 203, 1651-1656 (2006).
16. Niu, G. et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21, 2000-2008 (2002).
17. Kujawski, M. et al. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J. Clin. Invest. 118, 3367-3377 (2008).
18. Rosen, H. & Goetzl, E.J. Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat. Rev. Immunol. 5, 560-570 (2005).
19. Rivera, J., Proia, R.L. & Olivera, A. The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat. Rev. Immunol. 8, 753-763 (2008).
20. Matloubian, M. et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427, 355-360 (2004).
21. Shiow, L.R. et al. CD69 acts downstream of interferon-to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature 440, 540-544 (2006).
22. Schwab, S.R. & Cyster, J.G. Finding a way out: lymphocyte egress from lymphoid organs. Nat. Immunol. 8, 1295-1301 (2007).
23. Pappu, R. et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 316, 295-298 (2007).
24. Visentin, B. et al. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion and angiogenesis in multiple tumor lineages. Cancer Cell 9, 225-238 (2006).
25. Spiegel, S. & Milstien, S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat. Rev. Mol. Cell Biol. 4, 397-407 (2003).
26. Chae, S.S., Paik, J.H., Furneaux, H. & Hla, T. Requirement for sphingosine 1- phosphate receptor-1 in tumor angiogenesis demonstrated by in vivo RNA interference. J. Clin. Invest. 114, 1082-1089 (2004).
27. Kortylewski, M. et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 11, 1314-1321 (2005).
28. Bromberg, J.F. et al. Stat3 as an oncogene. Cell 98, 295-303 (1999).
29. Yu, C.L. et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 269, 81-83 (1995).
30. Li, L.C. et al. Small dsRNAs induce transcriptional activation in human cells. Proc. Natl. Acad. Sci. USA 103, 17337-17342 (2006).
31. Halak, B.K., Maguire, H.C. Jr. & Lattime, E.C. Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. Cancer Res. 59, 911-917 (1999).
32. Heinrich, P.C. et al. Interleukin-6-type cytokine signalling through the gp130/Jak/ STAT pathway. Biochem. J. 334, 297-314 (1998).
33. Zhong, Z., Wen, Z. & Darnell, J.E. Jr. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264, 95-98 (1994).
34. Okamoto, H. et al. EDG1 is a functional sphingosine-1-phosphate receptor that is linked via a Gi/o to multiple signaling pathways, including phospholipase C activation, Ca2+ mobilization, Ras-mitogen-activated protein kinase activation, and adenylate cyclase inhibition. J. Biol. Chem. 273, 27104-27110 (1998).
35. Kortylewski, M. et al. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat. Biotechnol. 27, 925-932 (2009).
36. Ghoreschi, K., Laurence, A. & O'Shea, J.J. Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat. Immunol. 10, 356-360 (2009).
37. Ram, P.T., Horvath, C.M. & Iyengar, R. Stat3-mediated transformation of NIH-3T3 cells by the constitutively active Q205L G?o protein. Science 287, 142-144 (2000).
38. Sabbadini, R.A. Targeting sphingosine-1-phosphate for cancer therapy. Br. J. Cancer 95, 1131-1135 (2006).
39. Carlson, C.M. et al. Kruppel-like factor 2 regulates thymocyte and T-cell migration. Nature 442, 299-302 (2006).
40. Graeler, M., Shankar, G. & Goetzl, E.J. Cutting edge: suppression of T cell chemotaxis by sphingosine 1-phosphate. J. Immunol. 169, 4084-4087 (2002).
41. Igarashi, J. et al. VEGF induces S1P1 receptors in endothelial cells: Implications for cross-talk between sphingolipid and growth factor receptors. Proc. Natl. Acad. Sci. USA 100, 10664-10669 (2003).